Clinical Edge Journal Scan

Increase in PSA testing after 2017 USPSTF recommendations


Key clinical point: Prostrate-specific antigen (PSA) testing increased after the 2017 United States Preventive Services Task Force (USPSTF) draft statement for prostate cancer screening.

Major finding: A relative increase of 12.5% was seen in the PSA testing rate during 2016-2019. A relative increase of 10.1%, 12.1%, and 16.2% was seen in men aged 40-54 years, 55-69 years, and 70-89 years. A significantly increasing trend of PSA testing was seen after the release of USPSTF draft in April 2017 (0.30 tests per 100 person-years for each bimonthly period; P < .001).

Study details: This retrospective cohort study of 8,087,565 men aged 40 to 89 years who underwent prostate cancer screening between 2013 and 2019.

Disclosures: This work was funded by National Institutes of Health/National Cancer Institute. The authors received grants, honoraria, and consulting/personal/speaker fees from various sources.

Source: Leapman MS et al. JAMA Oncol. 2021 Nov 11. doi: 10.1001/jamaoncol.2021.5143 .

Recommended Reading

Clinical Edge Journal Scan Commentary: Prostate Cancer November 2021
Federal Practitioner
Urine test for prostate cancer signals amount of aggressive tumor
Federal Practitioner
Higher prostate cancer incidence in MSH2 and MSH6 carriers
Federal Practitioner
Prostate cancer: Salvage LDR brachytherapy after EBRT shows good response
Federal Practitioner
mCRPC: Enzalutamide effective in real-world setting
Federal Practitioner